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Abstract The objective of this study was to assess
angiogenic activity by analyzing anti-CD105 and anti-
CD34 immunostaining in 20 cases of vascular malforma-
tions (VMs) and 20 cases of oral pyogenic granulomas
(OPG). In addition, the usefulness of these markers for the
differential diagnosis of these two oral tumors was evalu-
ated. The results showed no significant difference in mean
microvessel count between the anti-CD105 (P = 0.803)
and anti-CD34 (P = 0.279) antibody. The mean number of
vessels was 18.75 and 59.72 for oral VMs immunostained
with anti-CD105 and anti-CD34 antibody, respectively,
whereas in OPG the mean number was 20.22 and 48.09,
respectively. CD34 was found to be more effective than
CD105 in identifying blood vessels. However, the anti-
CD105 antibody seems to be more related to vascular
neoformation. Overall, this study supports the role of
angiogenic factors in the etiopathogenesis of oral VMs and
PG, but the results showed that quantification of angio-
genesis cannot be used as a marker for the differential
diagnosis of these two types of lesions.
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Introduction
Angiogenesis is defined as the growth and development of
new blood vessels from preexisting vasculature, and is
fundamental for a series of physiological and pathological
events such as inflammation, tissue repair, tumor growth,
and invasion and metastasis. The process is dynamic and
complex and involves the growth and migration of
endothelial cells and capillary morphogenesis [1]. Studies
have been conducted to better understand the main
angiogenic mechanisms in an attempt to develop new
therapeutic modalities that accelerate angiogenesis during
tissue repair or inhibit this process in different tumor
conditions [2].
Several biological markers with affinity for specific
epitopes on endothelial cells, such as von Willebrand fac-
tor/factor VIII, CD31, CD44, CD105 (endoglin), and
CD34, have been used to investigate the pathogenesis of
head and neck tumors such as pyogenic granulomas and
hemangiomas, which often exhibit similar clinical and
histopathological characteristics that impair their diagnosis
[1, 3].
CD105 (endoglin) is a 180-kDa homodimeric trans-
membrane glycoprotein, which is encoded by the CD105
gene located on chromosome 9q34. The endoglin is highly
specific for endothelial cells of capillaries, veins, and
arteries and is used as a marker for the assessment of
vascularization in both normal and neoplastic tissues.
Expression of CD105 is also observed in activated mac-
rophages, immature pro-erythroblasts, syncytiotropho-
blasts, and fibroblasts [2, 4].
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CD34 is a transmembrane glycoprotein of
105–120 kDa, which shows high specificity for endothelial
cells of blood vessels and for precursors of hematopoietic
cells. This protein is expressed in various neoplasms
including leukemia and vascular tumors, a fact suggesting
that CD34 immunostaining can be used as a diagnostic and
prognostic marker of these tumors [5].
Vascular anomalies are congenital errors in vascular
development. They frequently involve the head, neck, and
oral cavity. Subdivided into vascular tumors (hemangio-
mas) and vascular malformations (VMs), vascular anoma-
lies remain poorly understood. However, growing interest
and recent advances in the diagnosis, management, and
molecular characterization of these lesions are improving
treatment strategies [6]. Thus, the objective of this study
was to quantify angiogenic activity by analyzing anti-
CD105 and anti-CD34 immunostaining in oral VMs and
pyogenic granulomas (PG) to better understand the path-
ogenesis of these tumors. In addition, the usefulness of
these markers for the differential diagnosis of these two
oral lesions was evaluated.
Methods
Twenty oral VMs and 20 PGs cases obtained from the files
of the Pathological Anatomy Service, Discipline of Oral
Pathology, Department of Dentistry, Federal University of
Rio Grande do Norte, Brazil, were selected. For immuno-
histochemical analysis, 3-lm thick histological sections
were obtained from tissue specimens fixed in 10% formalin
and embedded in paraffin. The sections were mounted
on previously cleaned, grease-free glass slides prepared
with organosilane adhesive (3-aminopropyltriethoxy-
silane; Sigma Chemical Co., St. Louis, MO, USA), and
analyzed immunohistochemically using the streptavidin–
biotin complex. The sections were deparaffinized and
antigen retrieval was performed by immersion of the slides
in 0.4% trypsin, pH 7.9. Next, the slides were incubated
with the anti-CD34 (clone QBEnd101, Dako Corporation,
Glostrup, Denmark; 1:100, overnight) and anti-CD105
monoclonal antibodies (clone SN6H, Dako Corporation;
1:500, overnight). The reaction was developed with 0.03%
diaminobenzidine chromogen (Sigma) and the sections
were counterstained with Mayer’s hematoxylin.
All slides were examined independently by two
observers. The immunohistochemical staining pattern was
analyzed by light microscopy considering the following
parameters: angiogenic index determination based on the
number of microvessels immunostained with the anti-
CD34 and anti-CD105 antibodies, and qualitative analysis
of the CD34 and CD105 immunostaining pattern. The
angiogenic index of the tumors was determined based on
microvessel count as described by Maeda et al. [7]. Five
areas showing the highest vascularization were identified
subjectively by evaluating histological sections at 409
magnification, and vessels were counted under an Olympus
BX41 light microscope at 2009 magnification. The method
of Wakulich et al. [8] was used for the determination of the
intensity of anti-CD34 and anti-CD105 staining, and a
score ranging from 0 to 3 was attributed to subjectively
assess vessel staining intensity (0, absence of staining; 1,
focal or weak staining; 2, moderate or focally intense
staining, and 3, generalized intense staining). Sections in
which the step of incubation with the primary antibody was
omitted were used as negative control.
For analysis, any cell or endothelial cell group stained
separately from adjacent microvessels and other connective
tissue components, as well as, lumen-containing vessels
was counted as a single vessel. Branched and discontinuous
structures were also counted as vessels.
Since the data were analyzed by pairwise comparison of
the two groups, the Student’s t test was chosen for analysis,
with the level of significance set at 5% (P \ 0.05).
Results
Of the 20 oral VMs studied, 52.63% were males and
47.36% were females and mean of patient was 35.84 years.
All patients were older than 20 years. Most of patients
were whites (70.58%). In relation to OPG, 65% were
females with years mean of 34.73 and 66.6% were whites.
Qualitative analysis showed positive CD34 immuno-
staining in 100% of the oral VMs (n = 20) (Fig. 1) and
OPG (n = 20) (Fig. 2) cases studied. In contrast, CD105
immunoexpression was observed in 50% of VMs cases
(n = 10) (Fig. 3) and in 80% of PG cases (n = 16)
(Fig. 4). A more homogenous immunostaining pattern was
Fig. 1 Oral vascular malformation. Immunoexpression pattern of
anti-CD34 (SABC, 4009)
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obtained with the anti-CD34 antibody for both types of
tumors.
With respect to the intensity of CD105 immunostaining,
4 (20%) of the 20 pyogenic granuloma specimens ana-
lyzed were negative, 9 (45%) presented focal or weak
immunoexpression, 4 (20%) moderate and focally intense
staining, and 3 (15%) generalized intense staining. For
VMs, no staining was observed in 10 (50%) of the 20
specimens, 5 (25%) specimens presented focal or weak
immunoreactivity, and 5 (25%) presented moderate and
focally intense staining. No generalized intense immuno-
staining for this marker was observed in any of the VMs
cases.
CD34 expression was generalized and strong in most
(55%) PG cases, 4 (20%) cases presented focal or weak
expression, and 5 (25%) presented moderate or focally
intense staining. Analysis of CD34 expression in the he-
mangiomas showed strong or generalized staining in most
specimens (60%) and moderate and focally intense staining
in 8 (40%).
The mean number of blood vessels counted in VMs
specimens stained with the anti-CD105 and anti-CD34
antibodies was 18.75 (range 0.0–64.2) and 59.72 (range
18.0–115.08), respectively. For PG, the mean number of
blood vessels was 20.22 (range 0.0–38.6), and 48.09 (range
14.2–129.2) for specimens stained with the anti-CD105 and
anti-CD34 antibodies, respectively. Analysis by the Stu-
dent’s t test showed no statistically significant difference in
mean microvessel count between the two types of oral
tumors immunostained with the anti-CD105 or anti-CD34
antibody (Table 1).
However, the Student’s t test revealed a significant
difference in mean microvessel count between the two
antibodies tested for VMs and PGs (Table 2).
Discussion
In this study, angiogenic activity was quantified in oral
VMs and PGs by analysis of the expression of CD105 and
CD34 using anti-CD105 and anti-CD34 monoclonal anti-
bodies. Hemangiomas and vascular malformations are
congenital aberrancies of vascular development causing
identifiable birthmarks of the skin and mucosa and a var-
iable degree of underlying soft tissue abnormalities. Under
Fig. 2 Oral pyogenic granuloma. Immunohistochemical staining of
CD34 (SABC, 4009)
Fig. 3 Oral vascular malformation. Immunoexpression of anti-
CD105 in blood vessels (SABC, 4009)
Fig. 4 Oral pyogenic granuloma. Immunohistochemical staining of
CD105 in blood vessels (SABC, 2009)
Table 1 Angiogenic index determined by microvessel count
according to marker and type of lesion studied
Antibody Lesion n Mean SD t* P*
CD105 Vascular
malformation
20 18.75 22.478 0.252 0.803
Pyogenic granuloma 20 20.22 13.182
CD34 Vascular
malformation
20 59.72 36.533 -1.10 0.279
Pyogenic granuloma 20 48.09 30.031
SD standard deviation
* Student’s t test
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the global heading of vascular anomalies, these lesions
predominately occur within the head and neck and affect
approximately one in 22 children. Depending upon the size
and location, significant functional and esthetic impairment
can result from the growth of ‘problematic’ hemangiomas
or vascular malformations. Bleeding, pain, and disability
are also common. Thus, an in-depth understanding of the
natural history of vascular anomalies is critical for practi-
tioners who diagnose and manage these lesions [6].
Little is understood regarding the pathogenesis, molec-
ular make-up, and origin of vascular anomalies. The field,
however, is rapidly progressing. The identification of
molecular, genetic markers, and novel treatment protocols
has emerged over the past decade that is changing the
conceptual framework regarding the pathogenesis and
management of vascular anomalies [6].
Angiogenesis plays an important role in metastatic
mechanisms, vascularization of ischemic tissues, chronic
inflammatory processes, oligodendrogliomas, vascular
tumors such as hemangiomas, Kaposi’s sarcoma, angio-
sarcoma, and some autoimmune diseases. Netto et al. [2]
and Freitas et al. [3] agree about the clinical applications of
data obtained in experiments regarding vascular neofor-
mation for therapy aiming at the acceleration of angio-
genesis in order to promote tissue repair and the inhibition
of angiogenesis in various tumor conditions and regarding
the quantitation of angiogenesis as a diagnostic and prog-
nostic marker, thus representing an additional tool for
monitoring the progression and efficacy of treatment in
patients with these tumors.
In view of the different techniques recommended for the
quantification of angiogenesis, in this study the authors first
evaluated microvessel density, microvessel volume, and
microvessel count. The last parameter was then used for
the calculation of the angiogenic index since it was found
to be the simplest, most effective, and easiest method for
the quantification of angiogenesis in head and neck tumors.
Qualitative analysis showed positive immunostaining
for CD34 in 100% of the hemangioma and pyogenic
granuloma cases. In contrast, CD105 immunostaining was
only observed in 50 and 80% of hemangioma and pyogenic
granuloma specimens, respectively, demonstrating the high
sensitivity of CD34 immunostaining as reported by Gutt-
man et al. [9] for squamous cell carcinoma of the tongue.
Strong and generalized immunostaining of CD34 was
observed in both PG (55%) and VMs (60%). In contrast,
immunoexpression of CD105 was focal or weak in most
PG specimens (45%) and absent in most hemangiomas
(50%). These results agree with Guttman et al. [9] who
emphasized the importance of CD34 immunostaining
intensity in the study of angiogenesis.
Controversy exists regarding the evaluation of angio-
genesis using immunohistochemical markers such as CD34
and CD105. Soares et al. [1] and Martone et al. [10] defend
that CD105 represents an excellent indicator of angiogen-
esis, whereas Guttman et al. [9] and Ascani et al. [11]
emphasize the importance of CD34 in the study of angio-
genesis. This study showed a better efficacy of CD34, with
the observation of more uniform results that were more
easily interpretable, when compared to CD105. Neverthe-
less, no significant differences in the angiogenic indices
obtained by microvessel count were observed between
CD34 and CD105.
The CD34 and CD105 immunostaining results obtained
for oral VMs and PGs reflect the clinical and histopathol-
ogical similarity between the two types of tumors and, at
the same time, indicate the inefficacy of quantification of
angiogenesis as a differential diagnostic marker. These
findings agree with the results of Freitas et al. [3], who used
CD31 and von Willebrand factor antibodies for the quan-
tification of angiogenesis in oral hemangiomas and PGs
and concluded that these pan-endothelial markers should
not be used for the diagnostic differentiation of angiogenic
activity between these tumors by microvessel count.
In this study, the angiogenic indices obtained for oral
VMs and PGs using the anti-CD105 antibody were much
lower than those obtained with the anti-CD34 antibody.
Furthermore, CD105 immunostaining was negative in most
cases. Within this context, the small number of vessels and
the lack of CD105 staining in some specimens might
suggest that endoglin is an excellent marker of newly
formed vessels, whereas CD34 is a pan-endothelial marker
unable to differentiate newly formed vessels from preex-
isting ones [3, 12]. As a consequence, a larger number of
positive vessels were observed when using the latter anti-
body. Some investigators emphasize that endoglin is
preferentially expressed in proliferating vessels, with its
expression being associated with a poor prognosis [2, 13].
This marker has therefore been used for the evaluation of
the degree of tumor malignancy and for the estimation of
survival rates in many patients.
These results regarding CD105 immunostaining also
suggest that, based on the assumption that this antibody is
only expressed on newly formed vessels, tumor specimens
Table 2 Angiogenic index determined by microvessel count
according to type of lesion and marker studied
Lesion Antibody n Mean SD t* P*
Vascular
malformation
CD105 20 18.75 22.478 -4.271 \0.001
CD34 20 59.72 36.533
Pyogenic granuloma CD105 20 20.22 13.182 -3.80 0.001
CD34 20 48.09 30.031
SD standard deviation
* Student’s t test
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that are negative for this marker might be in a more
advanced or dormant stage in which a balance exists
between angiogenic (VEGF, bFGF, TNF-a, PDGF, and
IL-8) and antiangiogenic factors (TGF-b, TIMP-1, angio-
statin, endostatin, and TPS-1) [14]. Thus, in this series 50%
of oral VMs were in the non-proliferative phase and 80%
of OPGs were in the phase of development or endothelial
proliferation, a fact emphasizing the importance of angio-
genic mechanisms for the etiopathogenesis of these tumors
[15]. In this respect, it may be suggested that tumors in the
proliferative stage mainly presented an elevated activity of
vascular endothelial growth factor (VEGF). According to
Freitas et al. [3], VEGF is a potent mitogen for endothelial
cells, which is only expressed during the phase of tumor
development and is absent in histological sections of
involuted tumors or tumors in the phase of involution.
These results support the view that angiogenesis is an
important process in the growth and development of dif-
ferent head and neck tumors. However, these findings do
not emphasize only the similarity between oral VMs and
PGs and the relevance of CD105 and CD34 immuno-
staining for the study of vascular neoformations, but also
the tendency to consider that angiogenic factors play an
important role in the pathogenesis of these tumors reported
in several investigations [12, 14, 15]. However, the exact
role of the angiogenesis and its relationship with the
development of many tumors still needs to be clarified so
that it can be used as a safe tool for the identification of the
biological potential of the tumor and as a coadjuvant in
available treatments.
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